APLT INVESTOR ALERT: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Stockholder Class Action Lawsuit
February 10, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, both ...
Hosted on MSN1mon
Applied Therapeutics' Govorestat Faces 'Significant' Uncertainty in Galactosemia Treatment After FDA Rejection, RBC Says
Late Wednesday, the clinical-stage company said the FDA is unable to approve govorestat's new drug application for the treatment of classic galactosemia in its current form amid "deficiencies" in ...
Hosted on MSN2mon
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
It also significantly reduced plasma galactitol levels in adults and children with galactosemia. Additional studies provided strong efficacy and safety data across 185 classic galactosemia ...
Nature1y
1041 Galactose-Interference on Poct Glucose Analysis
Background and aims: Hypoglycemia is a typical, potentially life-threatening symptom in classical galactosemia with blood galactose considerably elevated (up to ∼100 mg/dl). Therefore we tested ...